Foghorn Therapeutics appoints Steven Bellon as CSO; Carl Decicco to retire by Jan 31, 2022

Foghorn Therapeutics Inc.

Carl Decicco steps down as CSO effective Jan 10, 2022; serves as Special Advisor through Jan 31, 2022 then retires.
Steven Bellon, PhD appointed as CSO effective Jan 10, 2022; joined Foghorn in 2016 as head of drug discovery.
Bellon brings 20+ years drug discovery experience from Amgen, Vertex, and Constellation Pharmaceuticals.
Decicco will receive base salary through Jan 31, 2022 and is eligible for FY2021 bonus; vested options exercisable until July 5, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Bellon

Chief Scientific Officer

FHTX · Foghorn Therapeutics Inc.

Effective: 2022-01-10
Filed: January 10, 2022, 6:59 PM ET

On this same date, the Company announced that Steven Bellon, PhD. had been appointed to serve as the Company’s Chief Scientific Officer, effective as of January 10, 2022.

Departed

Carl Decicco

Chief Scientific Officer

FHTX · Foghorn Therapeutics Inc.

Effective: 2022-01-10
Successor: Steven Bellon
Filed: January 10, 2022, 6:59 PM ET

Dr. Decicco will step down from his position as Chief Scientific Officer of the Company effective as of January 10, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven Bellon was appointed as Chief Scientific Officer at Foghorn Therapeutics Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

On this same date, the Company announced that Steven Bellon, PhD. had been appointed to serve as the Company’s Chief Scientific Officer, effective as of January 10, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Carl Decicco departed as Chief Scientific Officer at Foghorn Therapeutics Inc..

Action: stepped down
Role: Chief Scientific Officer

Exact text from the filing

Dr. Decicco will step down from his position as Chief Scientific Officer of the Company effective as of January 10, 2022

View on SEC.gov

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-000561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.